Rifaximin in Patients With Diabetic Gastroparesis
| 대상 질환 | Crohn Disease, Diabetic Gastroparesis |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Mayo Clinic |
| 상태 | 조기 종료 |
| 참여자 수 | 5 명 |
| 중재(약물) | Rifaximin |
| 시작일 | 2019년 6월 14일 |
| 완료일 | 2025년 4월 8일 |
| 결과 공개일 | 2026년 6월 22일 |
요약
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
Improvement in Bloating Based on Overall Questionnaire Scoring
| Intervention Treatment | 4 participants |
|---|---|
| Placebo Group | 1 participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Act — Janssen Research & Development, LLC
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severe — Janssen Research & Development, LLC
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn' — Janssen Research & Development, LLC
- A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Partic — Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease — Celularity Incorporated
- Loss of RESponse to Ustekinumab Treated by Dose Escalation — Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW